Mintz Levin's New York corporate practice represented its client, Oppenheimer & Co., Inc in the closing of two offerings recently.
Earlier this month Mintz Levin assisted Oppenheimer & Co., Inc. in the signing and closing of a $12 million registered direct offering for Columbia Laboratories. Columbia Laboratories is a specialty pharmaceutical company focused on developing and commercializing products for the women's healthcare and endocrinology markets that use its novel bioadhesive drug delivery technology.
Shortly thereafter, Mintz Levin again represented Oppenheimer & Co., Inc in the closing on a $12.7 million underwritten offering for Oncolytics Biotech Inc. The Canadian company focuses on the discovery and development of pharmaceutical products for the treatment of a variety of cancers. It trades on both the TSX and NASDAQ.
Representing Oppenheimer & Co., Inc. were corporate members Ivan Blumenthal and Todd Mason with assistance from associates Priya Agrawal, Samuel Effron and Merav Gershtenman. Richard Gervase, a member in the firm’s intellectual property practice also assisted in the transactions, as did Linda Bentley and Karen Lovitch, members in the health law practice.